DexCom (DXCM)

Generated: October 31, 2026

Green Dot

Statistics

Metric	Value
Last Close	$79.40
Blended Price Target	85.96
Blended Margin of Safety	8.3% Fairly Valued
Rule of 40 (Next)	62.5%
Rule of 40 (Current)	64.2%
FCF-ROIC	52.2%
Sales Growth Next Year	10.3%
Sales Growth Current Year	12.0%
Sales 3-Year Avg	14.4%
Industry	Medical Devices

Analysis

DexCom is a high-quality medical-device business with a credible runway for durable growth. Its continuous glucose monitoring technology addresses a large, underpenetrated diabetes market, while recent results show the business can still expand at a double-digit pace: third-quarter 2026 revenue increased 11% year over year to $1.344 billion, and management raised its full-year revenue outlook to approximately 12–13% growth.^[6] The opportunity is supported by broader use among people with type 2 diabetes, expansion beyond insulin users, international growth, and improved access through payers and pharmacies.

Revenue is more predictable than that of a conventional device manufacturer because sensors are consumed and replaced regularly, creating a recurring replacement cycle even though sales are generally transactional rather than subscription-based. DexCom’s moat is meaningful but not absolute: clinical evidence, regulatory clearances, software integration, brand trust, manufacturing scale, and accumulated user data reinforce the franchise. Leadership appears operationally capable and commercially disciplined. Overall, DexCom looks like a durable growth company whose principal challenge is converting a strong product position into broader mainstream adoption while staying ahead of increasingly capable rivals.

What the Company Does

DexCom develops and sells continuous glucose monitoring systems that measure glucose levels through a small wearable sensor, transmit readings to a receiver or smartphone, and provide alerts and analytics. Patients, caregivers, and clinicians use the data to manage diabetes and improve glucose control. DexCom makes money primarily from selling sensors and related hardware through distributors, pharmacies, healthcare providers, and direct channels.

The company’s revenue mix is best understood qualitatively rather than by a current percentage split. Recurring sensor consumption is the economic center of the business, supplemented by transmitters, receivers, software-enabled services, and associated commercial partnerships. The latest reported quarter showed worldwide revenue of $1.344 billion, with growth of 11% on both reported and organic bases.^[6]

Revenue Recurrence & Predictability

DexCom is primarily a transactional medical-device business with recurring demand, not a pure subscription company. Sensors have finite wear periods and must be replaced, so an established user typically generates repeated purchases. That replacement behavior gives DexCom greater visibility than a project-based business, although revenue remains exposed to reimbursement decisions, channel inventory, patient adherence, and new-customer acquisition.

No recent company disclosure located here states a precise percentage of revenue that is recurring or highly predictable. Qualitatively, predictability is strong at the installed-base level but less certain across the total business. New product launches, payer coverage, prescription flows, seasonal patterns, and international distribution can cause quarterly variability even when the underlying user base is expanding.

Revenue Growth Durability

DexCom can plausibly sustain above-market growth for several years because continuous glucose monitoring remains underpenetrated relative to the broader population living with diabetes. The most important levers are increasing adoption among people with type 2 diabetes, reaching patients who do not use insulin, expanding pharmacy and primary-care access, winning additional reimbursement, and growing internationally. The company highlighted positive CONNECT trial results for non-insulin-using type 2 diabetes patients in its second-quarter 2026 release, supporting the case for broader clinical use.^[3]

Structural tailwinds include rising diabetes prevalence, greater emphasis on measurable health outcomes, and growing acceptance of digital monitoring. Headwinds include reimbursement restrictions, affordability barriers, patient discontinuation, and competition from both established device companies and lower-cost entrants. Growth should remain durable, but the rate will eventually depend more on market expansion and retention than on early-adopter conversion.

Economic Moat

DexCom’s moat rests on a combination of regulatory approvals, clinical validation, product reliability, brand recognition, and an installed base that generates recurring sensor demand. Continuous glucose monitoring is a high-consequence product: accuracy, alert performance, ease of use, and dependable connectivity matter to patients and clinicians. Those requirements raise the barriers to entry beyond simply manufacturing a wearable sensor.

Switching costs are moderate rather than prohibitive. Patients may become accustomed to a device and its software ecosystem, but competing systems can win users through lower cost, better form factors, longer wear duration, or stronger integration with insulin-delivery platforms. DexCom’s moat is therefore defensible but contested. It can widen if the company converts clinical evidence into reimbursement and expands its data and software ecosystem; it can narrow if competitors match accuracy while offering simpler, cheaper, or more integrated products.

Management & Leadership

DexCom is not founder-led. Kevin Sayer has served as chief executive since 2015, giving him substantial tenure through the company’s expansion from a specialist diabetes-device maker into a global CGM platform. Recent execution has been solid: third-quarter 2026 revenue grew 11%, while management raised the midpoint of full-year revenue guidance and increased its operating-margin and adjusted-EBITDA-margin outlook.^[6]

Recent materials reviewed here do not provide a current, reliable insider-ownership percentage, so no precise figure is stated. Capital allocation appears centered on product development, manufacturing capacity, commercial expansion, clinical evidence, and operational scaling rather than on a major change in the company’s strategic identity. The key leadership test is maintaining innovation and affordability while managing competitive intensity.

Key Risks

Competition is the clearest strategic risk. Abbott and other device companies can pressure DexCom through lower prices, longer sensor wear, improved accuracy, simpler workflows, and integration with insulin pumps or broader digital-health platforms. A product gap in comfort, reliability, connectivity, or cost could increase churn and weaken pricing power.

Reimbursement and regulatory risk are also material. CGM adoption depends heavily on payer coverage, coding rules, prescription access, and evidence that supports use beyond intensive insulin therapy. Delays in approvals, unfavorable coverage decisions, or weaker-than-expected clinical adoption among type 2 and non-insulin users could reduce the size or speed of the addressable market.

Operationally, DexCom must maintain sensor quality, supply continuity, cybersecurity, and data reliability at global scale. Manufacturing disruptions, recalls, software outages, privacy incidents, or channel inventory corrections could damage trust quickly. Macro pressure on healthcare budgets may further encourage payers and providers to demand lower costs.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of November 7, 2026 November 7, 2026
GreenDot Stocks Screen Update — Week of October 31, 2026 October 31, 2026
GreenDot Stocks Screen Update — Week of October 24, 2026 October 24, 2026
GreenDot Stocks Screen Update — Week of October 17, 2026 October 17, 2026
GreenDot Stocks Screen Update — Week of October 10, 2026 October 10, 2026